The Bayesian Shift: Implementing the 2026 FDA Guidance for Modern Clinical Trials

Date: April 7, 2026
Duration: 60 Minutes
Time: 12 PM EST

In January 2026, the FDA released its landmark draft guidance, “Use of Bayesian Methodology in Clinical Trials of Drugs and Biological Products,” marking a definitive move away from the “frequentist-only” era. For industry professionals, this is a signal that the agency is officially open to “borrowing” data from the past to accelerate the cures of the future.

This webinar provides a deep dive into the practical application of this guidance. We will move beyond the theory of Bayes’ Theorem to explore how sponsors can use prior distributions, manage “prior-data conflicts,” and satisfy the FDA’s rigorous new requirements for computational transparency and simulation-based justifications.

Why You Should Attend

The 2026 guidance is not just a statistical update—it is a strategic pivot. You will learn:

Regulatory Clarity: Understand exactly what the FDA expects in a Bayesian protocol submission to avoid Refusal-to-File (RTF) actions.
Efficiency Gains: Learn how to use “informative priors” to reduce sample sizes in rare disease and pediatric trials.
Risk Mitigation: Discover how to use Bayesian “Time Machines” in platform trials to bridge data across different enrollment eras without introducing bias.
Competitive Edge: Gain insights into the FDA’s C3TI (Center for Clinical Trial Innovation) and how to participate in Bayesian demonstration projects.

Topics to be Covered:

The New Regulatory Standard: A section-by-section breakdown of the 2026 Draft Guidance.
The Bayesian Workflow: From choosing a Prior to updating the Likelihood and reaching the Posterior distribution.
- Self-Correction Note: We will specifically address the FDA’s new stance on “Dynamic Borrowing” where the model automatically down-weights prior data if it doesn’t align with current trial results.
Key Use Cases:
- Pediatric Extrapolation: Using adult data to support pediatric labels.
- External Controls: Leveraging Real-World Evidence (RWE) to replace or augment placebo arms.
- Oncology Dose-Finding: Accelerating Phase I/II through Bayesian Optimal Interval (BOIN) designs.
Operationalizing the Guidance: Requirement for Simulation Reports: Why “operating characteristics” (Type I error and Power) must be proven via thousands of simulated trials. Software & Data Integrity: FDA expectations for code reproducibility and Bayesian software validation (R, JAGS, Stan).
Direct Communication with the Agency: Strategies for “Early Engagement” meetings to gain alignment on Bayesian Success Criteria before the first patient is enrolled.

Who Will Benefit?

This session is designed for professionals who must translate the FDA’s “Current Thinking” into actionable development plans:

Regulatory Affairs Professionals: To ensure dossiers meet the new transparency and documentation standards.
Biostatisticians & Data Scientists: To master the specific “prior construction” and simulation requirements demanded by the 2026 guidance.
Clinical Program Managers: To evaluate if a Bayesian design can realistically shorten their specific trial’s timeline.
C-Suite Executives in Biotech: To understand the cost-saving potential of reduced sample sizes and adaptive designs.
Clinical Research Organizations (CROs): To better advise sponsors on innovative trial design services.

Learning Objectives

By the end of this webinar, participants will be able to interpret the FDA’s 2026 draft guidance on Bayesian methodology, design compliant Bayesian trial protocols using informative priors and dynamic borrowing, evaluate and mitigate prior-data conflicts, and justify operating characteristics through simulation. Attendees will also understand regulatory expectations for transparency, software validation, and early FDA engagement to strategically implement Bayesian designs that improve efficiency, reduce sample sizes, and maintain statistical rigor.

Speaker: Mukesh Kumar

PhD, RAC | CEO, FDAMap

For more info, fill the box below. We will contact you within 24 hrs.

Webinar Fee

Single Registration

$199

Group Registration (5 Persons)

$699

Group Registration (10 Persons)

$1199

Prices are in US Dollars.
The registration fee includes: The live webinar & all related course materials.

Terms & Conditions to register for the Webinar

Your Registration for the workshop is subject to following terms and conditions. If you need any clarification before registering for this webinar please email us at info@fdamap.com

Payment

We accept credit card, debit card, and PayPal.

Cancellations & Substitutions:

Written cancellations through fax or email (from the person who has registered for this conference) received at least 5 business days prior to the start date of the event will receive a refund — less a $30 administration fee. No cancellations will be accepted — nor refunds issued — within 5 business days before the start date of the event. You may however, choose to substitute the webinar for which you are registered with some other webinar in the future.

On request by email or fax (before the seminar) a credit for the amount paid minus administration fees ($30) will be transferred to any future FDA Map event and a credit note will be issued. No-shows will be charged the full amount.

Webinar material will be uploaded on the website 24 hours before the scheduled date of the webinar. In case it is not available on the website due to some technical issues, we will email the material a few hours before the start of the webinar.

In the event FDA Map cancels the webinar, FDA Map will issue a full refund to all the registrants for that webinar. Some topics and speakers may be subject to change without notice.